Sherpa Clinical Packaging and De:terminence Announce Initiative to Help Rare Disease Patients Climb Mountains

Sherpa Clinical Packaging and De:terminence Announce Initiative to Help Rare Disease Patients Climb Mountains Sherpa Clinical Packaging Partnership will Raise Funds Dedicated to Purchasing Equipment and Training Programs for Rare Disease Patients   Sacramento and San Diego, CA, August 21, 2018 — Sherpa Clinical Packaging and De:terminence are pleased to announce a joint fundraiser to […]

Read More

Orthotopic PDX Models with Quantitative Pathology End Points Provide a New Standard in Translational Oncology Drug Development

Orthotopic PDX Models with Quantitative Pathology End Points Provide a New Standard in Translational Oncology Drug Development   Reveal Biosciences Orthotopic Patient-Derived Xenografts (PDX) Despite the rise of personalized approaches to the treatment of cancer, translating these therapies into a clinical setting still poses an exceptional challenge. This is highlighted in drug development where research […]

Read More

Catalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals, Inc.

Catalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals, Inc. SOMERSET, N.J., August 14, 2018 – Catalent, Inc. (NYSE: CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the successful completion of the previously announced tender offer by Catalent Boston, […]

Read More

CERTIS ONCOLOGY PARTNERS WITH REVEAL BIOSCIENCES TO OFFER ADVANCED PRE-CLINICAL ONCOLOGY SERVICES

CERTIS ONCOLOGY PARTNERS WITH REVEAL BIOSCIENCES TO OFFER ADVANCED PRE-CLINICAL ONCOLOGY SERVICES   SAN DIEGO, AUGUST 13, 2018. Certis Oncology Solutions and Reveal Biosciences today announced a strategic partnership in which the two companies will collaborate to provide an innovative, next-generation suite of pre-clinical oncology services.   Under the agreement, Reveal will leverage its Artificial […]

Read More

FROM BENCH TO BEDSIDE – THE POTENTIAL OF REGENERATIVE MEDICINE

FROM BENCH TO BEDSIDE – THE POTENTIAL OF REGENERATIVE MEDICINE July 24, 2018 What if a patient could use her own cells to treat her disease? Bench-to-bedside therapeutics are possible with cell and gene therapies, and there has been steady growth in these industries over the past few years. According to the Alliance of Regenerative […]

Read More

Ask DEL BioPharma LLC: Selecting a CRO/CMO involves multiple considerations that are applicable to any component of the drug discovery/development process.  From the perspective of API manufacturing, it is critical to understand the following:

A company is looking to build a partnership with a CRO for the development of a new drug. This decision is a complex one and can play a significant role in the success for the company. What are the top 3 considerations that the company must make in their selection process to ensure that they […]

Read More